Extrafine single-inhaler triple therapy with BDP/FF/GB is effective for improving health-related quality of life and lung function in COPD.

A recent study explored exacerbation history to determine what it revealed about prognosis. The findings suggested that exacerbation severity history was predictive of future exacerbation status.

Investigators of a 3-year observational study identified independent risk factors for exacerbations related to chronic obstructive pulmonary disease (COPD) and successfully developed a novel risk ...

Please provide your email address to receive an email when new articles are posted on . Exacerbation risk factors in this population included GERD, chronic bronchitis, high symptom burden and ...

Clinical guidelines recommend use of exacerbation history in choosing therapies to predict the risk for chronic obstructive pulmonary disease exacerbations, but an analysis of data from three ...

Please provide your email address to receive an email when new articles are posted on . Single-inhaler fluticasone furoate/umeclidinium/vilanterol triple therapy ...

Credit: Scott Bodell/MedicalImages.com The authors outline preventative pharmacologic therapies for COPD exacerbations and a patient-tailored approach to management. Chronic obstructive pulmonary ...

Retrospective studies have shown that statins decrease the rate and severity of exacerbations, the rate of hospitalization, and mortality in chronic obstructive pulmonary disease (COPD). We ...

Acute exacerbations adversely affect patients with chronic obstructive pulmonary disease (COPD). Macrolide antibiotics benefit patients with a variety of inflammatory airway diseases. We performed a ...

Early initiation of maintenance medication in patients with moderate to severe COPD exacerbations is associated with reduced risk of future exacerbations and lower costs. Objectives: To examine the ...